Skip to main content
  • PASCAL Device Improves Severe Tricuspid Regurgitation Over Optimal Medical Therapy: CLASP II TR Trial

    The addition of tricuspid transcatheter edge-to-edge repair to optimal medical therapy using the PASCAL device produced greater reductions in tricuspid regurgitation (TR), reduced the need for future interventions, and resulted in a more substantial improvement in quality of life than medical therapy alone, according to the CLASP II TR trial. Findings were presented Monday November 1, at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 conference in San Diego.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details